Shortened LSD experience for adults with major depression
Tests LSD followed by risperidone to shorten the experience in adults with depression.
Plain-language title generated from the registry record
Registry title: Shortened LSD Intervention for Major Depressive Disorder
Key facts
- Where
- Baltimore, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 70 years old?
Source: NCT07503002, who can take part
Where in United States
- Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Johns Hopkins University
- Trial code
- NCT07503002
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience. This will be achieved by administering the drug risperidone 45-minutes after the administration of LSD.Read full original descriptionShow less
Shortened LSD Intervention for Major Depressive Disorder
The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience. This will be achieved by administering the drug risperidone 45-minutes after the administration of LSD.
Inclusion: Have given written informed consent; Meet DSM-5 criteria for MDD; MADRS >= 28 at screening Can read, write, and speak English fluently; Be judged by study team clinicians to be at low risk for suicidality.
Exclusion: Currently taking antipsychotics, or MAO inhibitors; Patients taking antidepressant medications and unable to taper; Moderate or strong CYP2D6 inhibitor antidepressants must undergo a washout period of 4 weeks or five half-lives prior to treatment; Currently taking CYP2D6 inhibitor other than an antidepressant that will be tapered; Currently taking efavirenz, Acetaldehyde dehydrogenase inhibitors such as disulfiram (Antabuse), Alcohol dehydrogenase inhibitors, or UGT1A9 inhibitors or UGT1A10 inhibitors such as phenytoin, regorafenib, eltrombopag; Epilepsy; Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia; Have a seizure disorder, multiple sclerosis, history of significant head trauma, CNS tumor, movement disorders or any neurodegenerative condition; Morbidly obese (>100 lbs. above ideal body weight, or BMI >=40, or BMI >=35 with high blood pressure or diabetes); Current or past history of meeting DSM-5 criteria for Schizophrenia, Psychotic Disorder (including substance-induced), Bipolar I or II Disorder or Major; Have a first degree relative with schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), or Bipolar I Disorder; Cardiovascular conditions: hypertension with resting blood pressure systolic >139 or diastolic >89, angina, heart rate > 99, a clinically significant ECG abnormality (e.g., atrial fibrillation, QTc > 450), TIA in the last 6 months stroke, peripheral or pulmonary vascular disease, cardiac valvulopathy; Women who are pregnant, nursing, or not practicing an effective means of birth control; Be judged by a study team clinician to be at risk for moderate or severe alcohol or benzodiazepine withdrawal; Body weight < 45 kg; Significant acute adverse reaction (e.g., dystonia) to an antipsychotic; Depression with psychotic features.